Poster Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma
Poster Efficacy and Safety of Loncastuximab tesirine and Rituximab (Lonca-R) Followed by DA-R-EPOCH in Previously Untreated High-Risk DLBCL: Preliminary Results from UCDCC#303, a UCHMC Phase II Trial
Poster Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response After CART: Planned Interim Futility Analysis of a Phase II Trial
Poster HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
Poster A phase II trial of loncastuximab tesirine in patients with previously treated Waldenström macroglobulinemia
Poster Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma
Poster Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma – Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
Poster A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Poster Quantitative Systems Pharmacology Modeling of Mipasetamab Uzopterine Integrates Knowledge and Defines Dosing Strategy for Patients With Sarcoma